Peter Kies - May 15, 2024 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)

Role
CFO
Signature
/s/ Peter Kies
Stock symbol
INO
Transactions as of
May 15, 2024
Transactions value $
-$33,485
Form type
4
Date filed
5/16/2024, 05:10 PM
Previous filing
Feb 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INO Common Stock Options Exercise +4.77K +21.53% 26.9K May 15, 2024 Direct F1, F2
transaction INO Common Stock Tax liability -$33.5K -2.56K -9.51% $13.07 24.4K May 15, 2024 Direct F3
holding INO Common Stock 375 May 15, 2024 By Spouse F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INO Restricted Stock Unit Options Exercise $0 -4.77K -33.33% $0.00 9.54K May 15, 2024 Common Stock 4.77K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 14,313 restricted stock units is as follows: 4,771 shares vested on May 15, 2024; 4,771 shares will vest on May 15, 2025; and 4,771 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F2 Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.
F3 The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.